The product information presented in these tables is not necessarily indicative of clinical efficacy, safety or improved treatment outcomes. Please refer to prescribing information for each product.
Aggrastat® Prescribing Information; Integrilin Prescribing Information; ReoPro Prescribing Information; Mousa SA et al. J Pharmacol Exp Ther 1998;286:1277-1284; Scarborough RM et al. Circulation 1999;100:437-444; Schneider DJ et al. Br J Clin Pharmacol 2011;72:672-682; Schneider DJ et al. Expert Rev Cardiovasc Ther 2004;2:903-913; Hashemzadeh M et al. Exp Clin Cardiol 2008;13:192-197
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
or call 1-800-FDA-1088.